Why tip someone for a job I'm capable of doing myself? I can serve food, I can drive a taxi, I can and do cut my own hair. I did, however, tip my urologist.
The way I tested it was to create Share link, then navigate to it in an incognito window on Desktop and try to RSVP. I am still unable RSVP without login. Perhaps it works without login if you explicitly invite a certain email.
In the late 80s/early 90s when I was kite-battling, it was common to use these glass coated strings. I haven't played in decades, but it does seem quite dangerous now that I think about it as an adult. I'm glad the practice is banned.
We live in a different age today in terms of safety awareness. I vividly remember playing with powerful fireworks during Diwali celebrations. We'd light them in our hands and hurl them skyward moments before they burst. Today the mere thought of this makes me shudder, and I can't even imagine my children playing this way.
In my youth, I participated in "kite fighting," a popular activity in my home country. During these battles, opponents maneuver their kites, attempting to cut each other's kite string through tricky aerial tactics. We used special kite strings coated in thin glass. The victor's prize was getting to keep their opponents kite. Around January, during the kite festival, there would be hundreds of kites in the air all dancing or playing with each other. A magnificent sight.
Your point is valid - we shouldn't take single-country risk in investing. Assuming you believe the world as a whole will get more productive and value creating, globally diversifying your stocks is the answer.
As an example that supports your point, the Japan stock market (Nikkei) peaked in 1989 and STILL has not returned to that high.
Congratulations on the launching to real users. I know how challenging that is and especially when your users are kids, I can imagine the pressure is much higher.
One piece of feedback on your use of the term AI. While adding the term "AI" to the description of /most/ products seems to increase their appeal, in products that are for children, to me, it reads like this product will be buggy at best and ends up decreasing the appeal. Words like researched, "smart", advanced, cutting-edge etc may be better suited. This is just one person's reaction, of course. I could be wrong--perhaps to non-engineers, reading "AI" on kids' products now has a more positive reaction.
A "real" demo video was exactly what I was looking for as well. Since the concept is so novel, seeing the product in action would increase my trust, and willingness to buy significantly. My skeptical side made me wonder if demos with real children had been left out on purpose so it doesn't make the product look bad - probably not what you were going for.
The topics aren't perfect either, unfortunately. For example, Sublime Text, as we know it, was first released in 2008 while the topic trends data you linked shows it being the leader in 2004.
Great to hear and congratulations to the team. Amazing persistence. I used to be a huge Textmate fan - it was so revolutionary in its time. Unfortunately, I think it is too late. The Google Trends comparison of Textmate, Sublime Text and VS Code tells the story: https://trends.google.com/trends/explore?date=all&geo=US&q=%...
You must have taken the standard RIPE therapy which consists of 4 powerful drugs: rifampin, isoniazid, pyrazinamide, and ethambutol. Plus sometimes doctors add some other pills to control specific side effects a patient may be having like nausea or dizziness.
I really appreciate you adding your personal perspective. A big problem in TB today is that the “western” world sees it mostly as a “not-my-problem” kind of disease. What people forget is that TB is airborne and that the world is getting smaller. It will start impacting everyone.
TB is everyone’s problem and more investment should be made by the wealthier countries toward it’s care.
True that they're being cautious to protect their investment in the drug. In the case of TB, it's taken seriously enough that the drugs used to treat MDR/XDR TB are taken under close medical supervision, especially brand new drugs like Bedaquiline and Delamanid. They are usually administered under DOT (directly observed therapy) where a patient is required by law to take the drugs daily in front of a witness, or with lower-risk patients they use VDOT (Video Directly Observed Therapy) where patients can use an app to video record themselves taking the medicine daily and submit the evidence to the local Department of Health. In cases where patients don't comply to treatment, they can be arrested and isolated due to the public health risk.
The reason is that in some trials of Delamanid, a rare but serious side effect called QT prolongation was uncovered. To monitor for this side effect, a patient needs to have regular EKGs done. Since Delamanid is not approved in many countries yet (including the US), Otsuka wants to eliminate even the smallest chance of a patient complication which could delay their approval process. So they call for full hospitalization while the patient is on the drug.
For brand new drugs that cure critical illnesses, the FDA has a compassionate use program (officially called Expanded Access) which allows drugs that are not fully approved yet to be used immediately by very ill patients. Otsuka requiring months of hospitalization to monitor for a rare side effect was just wrong and against the spirit of compassionate use access IMO. This side-effect is easily and cheaply monitored by regular EKGs at a local primary care doctor or urgent care clinic.
This advancement is especially promising because access to Delamanid (a drug similar to Pretomanid) is very difficult for patients in many countries. The company that developed Delamanid, Otsuka Pharmaceutical, has been extremely restrictive in allowing access to it.
I know someone critically ill who was petitioning Otsuka for access to Delamanid under compassionate use, but Otsuka would only agree to give access if the patient stayed in a hospital for 4-6 months. This is just a crafty way for pharma companies to refuse access since they know the cost of months of hospital stay is not affordable or practical. Luckily in this instance, TB Alliance and others fought with Otsuka to get this patient access to the drug.
In many high-need countries (India/Africa/China etc), desperate doctors frequently just lie to Otsuka about the patient staying in the hospital in order to get access to the drug.
Opening access to Pretomanid is a great advancement!
That is certainly possible. However, the trick here is hidden in your saying the idea is "fully fleshed." Our temptation often is to fully flesh ideas either in our own imagination, with our friends, or with internet research. If instead you actually flesh out ideas by speaking to customers, building prototypes and testing them, gathering real user data, and even actual sales data, then definitely yes that idea could be worth a ton. But if this idea is fully fleshed out like in a research paper where you've spent 24 hours in a library, then your case is much harder to make.